



- Use total bilirubin. Do not subtract direct reading or conjugated bilirubin.
- Risk factors = isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin < 3.0 g/dL (if measured)
- For well infants 35-37 6/7 wk can adjust TSB levels for intervention around the medium risk line. It is an option to intervene at lower TSB levels for infants closer to 35 wks and at higher TSB levels for those closer to 37 6/7 wk.
- It is an option to provide conventional phototherapy in hospital or at home at TSB levels 2-3 mg/dL (35-50 mcmol/L) below those shown but home phototherapy should not be used in any infant with risk factors.

FIGURE 1



- The dashed lines for the first 24 hours indicate uncertainty due to a wide range of clinical circumstances and a range of responses to phototherapy.
- Immediate exchange transfusion is recommended if infant shows signs of acute bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, high pitched cry) or if TSB is ≥5 mg/dL (85 μmol/L) above these lines.
- Risk factors - isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis.
- Measure serum albumin and calculate B/A ratio (See legend)
- Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin
- If infant is well and 35-37 6/7 wk (medium risk) can individualize TSB levels for exchange based on actual gestational age.

FIGURE 2



22
17
12
7
3
Infants at lower risk (≥ 38 wk and well)
Infants at medium risk (≥ 38 wk + risk factors or 35-37 6/7 wk. and well
Infants at higher risk (35-37 6/7 wk. + risk factors)
8 h
24 h
48 h
72 h
96 h
5 Days
6 Days
7 Days
Age

FIGURE 3



Total Serum Bilirubin (mg/dL)
25
20
15
10
5
428
342
257
171
85
0
μmol/L
Infants at lower risk (≥ 38 wk and well)
Infants at medium risk (≥ 38 wk + risk factors or 35-37 6/7 wk. and well
Infants at higher risk (35-37 6/7 wk. + risk factors)
24 h
48 h
72 h
96 h
5 days
6 days
7 days
Age

FIGURE 4



25
20
15
10
5
428
342
257
171
85
0
Infants at lower risk (≥38 wk and well)
Infants at medium risk (≥38 wk + risk factors or 35-37 wk and well)
Birth
24 h
48 h
72 h
96 h
5 Days
6 Days
7 Days
Age

FIGURE 5



Concentration
25000
20000
15000
10000
5000
0
ng/ml
20400
11500
6450
Concentration
1.5 mg/kg
3.0 mg/kg
4.5 mg/kg

FIGURE 6



13
12
11
10
9
8
7
6
12.44
12.43
11.15
10.9
9.99
8.31
Baseline
6
12
24
48
72
Placebo
1.5 mg dose
3.0 mg dose
4.5 mg dose

FIGURE 7




13
12
11
10
9
8
7
6
mg/dL
12.44
12.43
11.15
10.9
9.99
8.31
Baseline
6
12
24
48
72
Time post dose
4.5 mg/kg
Placebo

FIGURE 8



	baseline	6	12	24	48	72
4.5 mg/kg	0	1.69	1.9	0.93	0.8	0.15
Placebo	0	0.49	0.42	1.99	2.78	3.7

FIGURE 9



PT starts
18
16
14
12
10
8
6
4
2
0
0
2
6
12
24
29
35
41
11.5
13.5
12.6
13.6
15.2
15.2
13.2
11.5
11.3
Bili
Threshold

FIGURE 10



PT starts
20
18
16
14
12
10
8
6
4
2
0
Baseline
0.75
2
6
12
24
48
56
63
72
9.7
11.4
11.9
11.6
12.7
13.9
10.4
14.5
14.1
13.6
TSB
Threshold

FIGURE 11



Proposed Nomogram for Treatment of High Risk Infants
Total Serum Bilirubin (mg/dL)
0
2
4
6
8
10
12
14
16
18
20
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Age
Phototherapy - high risk
Transfusion - high risk
Stannsoporfin - high risk

FIGURE 12A



Proposed Nomogram for Treatment of Medium Risk Infants
Total Serum Bilirubin (mg/dL)
25
20
15
10
5
0
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Age
Phototherapy - med risk
Transfusion - med risk
Stannsoporfin - med risk

FIGURE 12B



Proposed Nomogram for Treatment of Low Risk Infants
Total Serum Bilirubin (mg/dL)
30
25
20
15
10
5
0
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Age
Phototherapy - low risk
Transfusion - low risk
Stannsoporfin - low risk

FIGURE 12C



6 hours
12
24
48
72 hours
15
10
5
0
-5
-10
-15
-20
-25
-30
-35
Placebo
1.5 mg dose
3.0 mg dose
4.5 mg dose
Data Source:
Table 14.2.3.1

FIGURE 13



80
70
60
50
40
30
20
10
0
Baseline
6
12
24
48
72 hours
Placebo
1.5 mg dose
3.0 mg dose
4.5 mg dose
Data Source:
Table 14.2.3.3

FIGURE 14